{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:06:56Z","timestamp":1781086016867,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:00:00Z","timestamp":1455840000000},"content-version":"vor","delay-in-days":445,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1378\/chest.14-0117","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T09:31:11Z","timestamp":1403775071000},"page":"1531-1542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD"],"prefix":"10.1016","volume":"146","author":[{"given":"James F.","family":"Donohue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola A.","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Make","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tosiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 pt 2","key":"10.1378\/chest.14-0117_bib2","first-page":"S77","volume":"152","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1378\/chest.14-0117_bib3","first-page":"798","volume":"46","author":"Pauwels","year":"2001","journal-title":"Respir Care"},{"issue":"1","key":"10.1378\/chest.14-0117_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/15412550903499498","article-title":"The safety and efficacy of arformoterol and formoterol in COPD","volume":"7","author":"Hanania","year":"2010","journal-title":"COPD"},{"issue":"8","key":"10.1378\/chest.14-0117_bib5","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1172\/JCI60324","article-title":"Pathogenesis of chronic obstructive pulmonary disease","volume":"122","author":"Tuder","year":"2012","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1378\/chest.14-0117_bib6","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.158.6.9709003","article-title":"Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program","volume":"158","author":"van den Boom","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1378\/chest.14-0117_bib7","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1378\/chest.13-0453","article-title":"Characteristics of undertreatment in COPD in the general population","volume":"144","author":"Ingebrigtsen","year":"2013","journal-title":"Chest"},{"issue":"11","key":"10.1378\/chest.14-0117_bib8","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med"},{"issue":"12","key":"10.1378\/chest.14-0117_bib9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1378\/chest.14-0117_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0954-6111(99)90004-5","article-title":"Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitaci\u00f3n Obstructiva al Flujo aEreo","volume":"93","author":"Miravitlles","year":"1999","journal-title":"Respir Med"},{"issue":"5 pt 1","key":"10.1378\/chest.14-0117_bib11","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.14-0117_bib12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/COPD.S34186","article-title":"Exacerbation frequency and course of COPD","volume":"7","author":"Halpin","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"10.1378\/chest.14-0117_bib13","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0012-3692(15)52821-3","article-title":"Comments on the Salmeterol Multicenter Asthma Research Trial","volume":"130","author":"Seymour","year":"2006","journal-title":"Chest"},{"issue":"13","key":"10.1378\/chest.14-0117_bib14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1002074","article-title":"The FDA and safe use of long-acting beta-agonists in the treatment of asthma","volume":"362","author":"Chowdhury","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1378\/chest.14-0117_bib15","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMp1104375","article-title":"Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma","volume":"364","author":"Chowdhury","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.14-0117_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/COPD.S39018","article-title":"The safety of long-acting \u03b22-agonists in the treatment of stable chronic obstructive pulmonary disease","volume":"8","author":"Decramer","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1378\/chest.14-0117_bib17","first-page":"CD010177","article-title":"Long-acting beta2-agonists for chronic obstructive pulmonary disease","volume":"10","author":"Kew","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1378\/chest.14-0117_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/thx.2009.128082","article-title":"Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care","volume":"65","author":"Feary","year":"2010","journal-title":"Thorax"},{"issue":"8","key":"10.1378\/chest.14-0117_bib19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/thx.2010.136077","article-title":"TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results","volume":"65","author":"Calverley","year":"2010","journal-title":"Thorax"},{"key":"10.1378\/chest.14-0117_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/COPD.S23816","article-title":"Safety of indacaterol in the treatment of patients with COPD","volume":"6","author":"Donohue","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1378\/chest.14-0117_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rmed.2010.11.027","article-title":"Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD","volume":"105","author":"Worth","year":"2011","journal-title":"Respir Med"},{"issue":"2","key":"10.1378\/chest.14-0117_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1378\/chest.11-1597","article-title":"Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort","volume":"142","author":"Wilchesky","year":"2012","journal-title":"Chest"},{"key":"10.1378\/chest.14-0117_bib23","unstructured":"Brovana (arformoterol tartrate) [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2011."},{"issue":"1","key":"10.1378\/chest.14-0117_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1378\/chest.129.1.15","article-title":"SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol","volume":"129","author":"Nelson","year":"2006","journal-title":"Chest"},{"issue":"10","key":"10.1378\/chest.14-0117_bib25","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","article-title":"Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD","volume":"107","author":"Donohue","year":"2013","journal-title":"Respir Med"},{"issue":"2","key":"10.1378\/chest.14-0117_bib26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clinthera.2007.02.009","article-title":"Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial","volume":"29","author":"Baumgartner","year":"2007","journal-title":"Clin Ther"},{"issue":"2","key":"10.1378\/chest.14-0117_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1586\/ers.10.16","article-title":"Arformoterol tartrate in the treatment of COPD","volume":"4","author":"Cazzola","year":"2010","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"10.1378\/chest.14-0117_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1753465808089455","article-title":"Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance","volume":"2","author":"Donohue","year":"2008","journal-title":"Ther Adv Respir Dis"},{"issue":"8","key":"10.1378\/chest.14-0117_bib29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1378\/chest.14-0117_bib30","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1378\/chest.14-0117_bib31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1378\/chest.14-0117_bib32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMe068307","article-title":"Treating COPD\u2014the TORCH trial, P values, and the Dodo","volume":"356","author":"Rabe","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215515237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215515237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:24:56Z","timestamp":1757921096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215515237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0012369215515237"],"URL":"https:\/\/doi.org\/10.1378\/chest.14-0117","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.14-0117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American College of Chest Physicians. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}